Table 1 The methodological details of analyzed studies
Author, date | Design study | Databases search | Eligibility criteria | Search period | Population | Intervention/ comparison | Outcome | Refs |
|---|---|---|---|---|---|---|---|---|
Buglio et al., 2022 | Human systematic review | MEDLINE-PubMed, Cochrane, and EMBASE | Randomized Clinical Trials | Over 10 years up to May, 2021 | 151 patients with AD (83 women and 68 men)/aged between 49 and 80 years old | Original studies involving patients with AD who were treated with RV | RV brings beneficial effects to patients with AD | [56] |
Tosatti et al., 2022 | Human systematic review | MEDLINE, CENTRAL, Embase, CINAHL, Web of Science, and Scopus | Randomized, placebo-controlled, clinical trials | Up to August, 2021 | 241 patients with AD, with 117 patients allocated to the placebo group with a mean age of 75.4 ± 5.2 years, and 124 patients in the intervention group | Original studies involving patients with AD who were treated with RV | RV is effective for cognitive and functional decline in AD patients, when compared with a placebo group | [60] |
Kocatürk et al. 2022 | Human systematic review | PubMed, web of Science, Korean Journal Database, Russian Science, Citation index, ScieLO Citation index, Cochrane Library and Scopus | Not restricted | Up to 16 April, 2021 | 186 patients with AD | Original studies involving patients with AD who were treated with RV | RV improvs cognitive, functional prognosis and quality of life in AD patients | [58] |
Xu Lou et al., 2023 | Human systematic review | PubMed, Web of Science, Scopus, and Cochrane Library | Randomized, placebo-controlled, clinical trials, and systematic studies | 2018 to 2022 | 159 patients with AD (77 patients received RV/ 75 received placebo) | Original studies involving patients with AD who were treated with RV | RV acts as an AD antagonist, fulfilling neuroprotective functions, improving inflammation levels, and promoting cognitive functions | [61] |
Chen et al., 2019 | Animal systematic review and meta-analysis | Google Scholar, PubMed, Web of Science | Not restricted | Up to August, 2019 | 19 studies describing the efficacy of RV in rodent AD models by electronic and manual retrieval | Laboratory animals of any breed, age, sex, or strain/ control and resveratrol administration groups based on route of administration, duration of treatment and dosage | RV can be used as anti-AD in the pre-clinical studies, and RV has neuroprotective effects in AD models | [57] |
Komorowska et al., 2020 | Animal systematic review | PubMed | Not restricted | Over 10 years up to February, 2020 | N/A | Animal models of AD received RV | RV can be effectively used in the prevention of AD | [59] |